ASX ANNOUNCEMENT

Q2 FY25 Results Investor Briefing Invitation

MELBOURNE, Australia (5 February 2025) – Lumos Diagnostics Holdings Ltd (ASX:LDX, "Lumos" or the "Company") a leader in rapid, point-of-care diagnostic technologies, will be presenting its Q2 FY25 financial results today at 10:15am (AEDT). The accompanying presentation is attached to this release.

During the briefing, Chief Executive Officer, Doug Ward and Chief Financial Officer, Barrie Lambert will present an overview of the results and discuss recent progress. This will be followed by a Q+A session.

Participants can pre-register ahead of time via the following link:

https://us02web.zoom.us/webinar/register/WN_v9-IXNkeQeS6lXOLiAUYCQ

Once the registration form is completed, investors will receive a confirmation email with details on how to access the briefing. If you would like to ask a question during the briefing, please send your question ahead of the session to: george.kopsiaftis@irdepartment.com.au.

The Lumos team looks forward to welcoming those shareholders and potential investors who are able to attend.

-Ends-

This announcement has been approved by the Lumos Company Secretary.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:
Haley Chartres – Australia
H^CK Director
haley@hck.digital
+61 423 139 163

Investor Contact:
George Kopsiaftis
IR Specialist, IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:
Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205, Australia
+61 3 9087 1598

Lumos Diagnostics Holdings Limited
Q2 FY25 Investor Briefing

5 February 2025

Financial information is shown in USD unless otherwise stated.

lumosdiagnostics.com

Disclaimer and Important Information

This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company).

The information contained in this document ("Document") has been prepared by Lumos Diagnostics Holdings Limited (referred to as "Lumos" or "Company"). This Document is current as at the date of this Document and should be read in conjunction with other Lumos periodic and continuous disclosure announcements filed with the Australian Securities Exchange (ASX), available at www.asx.com.au.

The information in this Document is not intended to form the basis of any investment decision in relation to the Company or its assets and should not be considered as a recommendation to the Recipient to acquire securities in the Company. This Document is not a prospectus, profile statement or disclosure document and does not constitute an offer or invitation to acquire securities or otherwise invest in the Company, and no agreement to subscribe for securities will be entered into on the basis of this Document.

No representation or warranty, expressed or implied, is or will be made, and no responsibility or liability is or will be accepted by the Company, any of their respective officers, servants, agents or advisers (collectively "Limited Parties") as to or in relation to the accuracy, reasonableness, completeness or reliability of the information in this Document or any other written or oral information made available to any Recipients or their advisers. Any liability therefore is hereby expressly disclaimed. In particular, no representation or warranty is given as to the achievability or reasonableness of any future projections, management estimates or plans, prospects, returns or forecasts.

To the fullest extent permitted by law, the Limited Parties will not have any responsibility or liability for any loss or damage (whether foreseeable or not), however arising (including as a result of negligence), in relation to or in connection with the provision of this Document, the Recipient's or any other person's purported reliance on this Document, the failure to provide information of which any of the Limited Parties becomes aware or any errors in or omissions from this Document.

None of the Limited Parties makes or gives any representation, warranty or guarantee, express or implied, that the information in this Document is accurate, current, reliable or complete, has been or will be audited or independently verified, or that reasonable care has been taken in compiling, preparing or furnishing it. Various statements in this Document constitute statements relating to intentions, future acts and events including forecast financial information ("Forward Looking Statements"). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that may cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed herein.

The Limited Parties do not make or give any representation, warranty or guarantee, express or implied, that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable. No historical financial information, forecast financial information, estimates or projections contained in this Document or any other financial information derived from that information, can be relied upon as a promise or representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of achievement or reasonableness of any Forward Looking Statement, forecast financial information or other forecast. The Limited Parties do not undertake any obligation to (and expressly disclaim any obligation to) provide the Recipients with access to any additional information or to correct any inaccuracies herein which may become apparent or to disseminate any updates or revisions to any Forward Looking Statements in this Document to reflect any change in expectations in relation to any such statements or any change in events, conditions or circumstances on which any such statement is based.

This document also contains statistics, data and other information relating to markets, market sizes, market shares, market positions and other industry data pertaining to the Lumos business and markets. Such information is generally based on independent market and industry data or research. Lumos has not independently verified and cannot give any assurances as to the accuracy and completeness of the information sourced from market and industry data or research contained herein. Accordingly, the accuracy and completeness of such information is not guaranteed. There is no assurance that any of the forecasts or projections contained in the independent market and industry data or research will be achieved. Forecasts and projections involve risks and uncertainties and are subject to change based on various factors. You should note that market data and statistics are inherently predictive and subject to uncertainty and not necessarily reflective of actual market conditions.

Neither the receipt of this Document by any person nor any information contained in it or supplied with it or subsequently communicated to any person in connection with a proposed investment in the Company constitutes, or is to be taken as constituting, the giving of investment or financial product advice (or any other advice) to any such person. Each such person should make their own independent assessment of the merits or otherwise of investing in the Company and should seek their own professional advice in respect of any future investment opportunity and not act on the basis of any matter contained in this Document. In providing this Document, the Company has not considered the objectives, financial position, taxation situation or other needs of any particular Recipient.

The distribution of this document in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this document who are not in Australia, should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States.

Non-IFRS financial measures

Recipients should note that certain financial data included in this Document is not recognised under the AAS and is classified as 'non-IFRS financial information' under Regulatory Guide 230 'Disclosing non-IFRS financial information' published by ASIC. The Company believes that this non-IFRS financial information provides useful information to users in measuring the financial performance and condition of Lumos. The non-IFRS financial measures do not have standardised meanings under AAS, and therefore may not be comparable with similarly titled measures presented by other entities, nor should these be interpreted as an alternative to other financial measures determined in accordance with AAS. Investors are cautioned not to place undue reliance on any non-IFRS financial information, ratios and metrics included in this Document.

Key Highlights – Q2 FY25

Key Highlights - 2Q FY25

- Unaudited revenue of US$2.9 million for the quarter, up 71% compared to PCP (Q2 FY24 - US$1.7 million).
- Product revenue was up 200% over same period last year and Services revenue was up 53% on PCP
- FebriDx - CPT PLA code approval in the US, effective 1 January 2025 – reimbursement rate of US$41.38 per test
- FebriDx - BARDA partnership announced in October 2024 to support CLIA waiver and paediatric studies with non-dilutive funding up to US$8.3 million. CLIA Waiver study commenced 19 December 2024 with first patient tested
- Successful A$10.0 million capital raise completed October 2024 – well supported by Tenmile and Ryder Capital
- Cash balance of US$5.5 million as at 31 December 2024, prior to receipt of BARDA milestone payments of US$0.9 million in January 2025. Proforma cash balance of US$6.4 million

Financials Summary (to 31 December 2024)

(Quarterly, US$ in thousands)

REVENUE ($'000)



REVENUE MIX



NET CASH GENERATION ($'000)*



COMMENTARY

- **Revenue** – US$2.9 million in Q2 FY25, up 71% on pcp. Revenue for 1HY FY25 of US$6.3 million, up 128% on 1HY FY24 of $2.8 million
- **Services** revenue was US$2.3 million in Q2 FY25, up 53% on pcp, with a large contribution from development services under the Hologic fFN Development Agreement and the intellectual property licensing revenue associated with the IP Agreement. Impacted by US$0.59 million due to the extended timeline for the project from 20 to 24 months.
- **Products** revenue was US$0.6 million in Q2 FY25, up 200% on pcp. Major contribution from ViraDx, plus increasing contribution from FebriDx.
- **Net cash outflow** of US$3.9 million in Q2 FY25, affected by inventory stocking ahead of US flu season and FebriDx CLIA waiver study preparation costs.
- **Successfully completed retail entitlement component** on 8 October 2024 for A$6.9 million, bringing the total capital raise to A$10.0 million, strongly supported by new and existing shareholders, Tenmile and Ryder Capital.
- **Cash balance as at 31 December 2024** of US$5.5 million. Pro-forma of US$6.4 million (including receipt of BARDA milestone payments in Jan 25 of US$0.9 million, which is reimbursement for costs incurred in Q1 and Q2).

*Net cash generation comprised of operating and investing cash flow, plus lease payments.

Product Update

FebriDx Update

- **Reimbursement amount: PLA code approval – Dec 2024**
  - The FebriDx PLA code has been approved and published on the Clinical Lab Fee Schedule and is effective from January 1, 2025. Reimbursement rate of US$41.38 per test
- **BARDA partnership agreement - Oct 2024**
  - To support CLIA waiver and pediatric studies: non-dilutive funding up to US$8.3m
- **CLIA waiver clinical study commenced – Dec 2024**
  - Trial commenced on 19 December 2024 - first patient tested
  - Anticipate completion by forthcoming US Spring season
  - CLIA waived labelling expands market by 15 times current moderate complex opportunity (market size >US$ 1 billion)
- **Partnerships / Agreements**
  - **Post reporting date:** Lumos partners with MedPro Associates for FebriDx national contract sales coverage across hospital and primary care markets in the US
  - Awarded DAPA certification for procurement to US Military Services

ViraDx™ – Point-of-Care test for key respiratory infections

ViraDx highly relevant POC test for post-pandemic environment:

- SARS-CoV-2 pandemic increased consumer and healthcare point-of-care testing
- ViraDx is a 3-in-1 test for COVID-19/Flu A/Flu B

ViraDx market update:

- **Stocking orders**
  - Majority of product sales during the quarter, with stocking orders received in October in preparation for the upcoming flu season
  - US flu season commenced some 6 – 8 weeks later than expected, impacting product sales in November and December
- **Competition**
  - ViraDx continues to see an increase in new customer adoption due to the rise in infection rates - despite the US market experiencing growing competition from international organizations, with aggressive pricing

Lumos Product Roadmap | Women's Sexual Health - $10B

PREVALENCE

30-40% of women
>10M heath care visits annually



CLINICAL NEED

Multiple infectious organisms
Similar symptoms
Different treatments

POC DIAGNOSTIC NEED

Rapid testing on site
Identify & treat at patient visit
Easy to use by clinic staff

Services Update

Hologic - Strategic Partnership - Recap

Historic relationship with Lumos <> Hologic – working together at multiple levels

- Multiple services contracts signed during FY2023
- Two new agreements signed in FY24 for the development of an improved version of one of Hologic's leading in-market women's health products, **Fetal Fibronectin (fFN)**, including adapting it for use on Lumos' proprietary reader platform[1]
- fFN is a biomarker indicating a heightened risk of pre-term delivery when present in cervicovaginal secretions and the largest segment in the pre-term diagnostic test kit market
- The **IP Agreement** for US$10.0 million provides Hologic with an exclusive license in the field of fetal fibronectin to the Lumos proprietary reader and POC technologies that will be incorporated into the next generation product[1]
- **Development Agreement** valued at up to US$4.7 million in payments over an estimated 24 month period, dependent on the achievement of specified milestones, outlined below[1]:
    - **Phase 1: Product Definition and Planning** - define the parameters for the product and establish a project plan US$0.4 million - completed;
    - **Phase 2: Assay Feasibility** - conduct work to demonstrate the assay is able to detect the biomarkers US$0.6 million – milestone 1 completed /milestone 2 in-progress; and
    - **Phase 3: System Prototype Delivery** – deliver a working prototype of the system - US$3.7 million – contains 6 milestones, commenced milestone 1, planning and initial design activities

✓ **US$10m IP Agreement payment received**

✓ **Phase 1 completed (US$0.4m received)**

✓ **Phase 2 in progress (US$0.3m received)**

Pre-term diagnostic test kit market

Sales (US$420m pa)[2]



[1]ASX announcements 11 January 2024, 15 January 2024, 16 January 2024, 6 May 2024, 4 June 2024, 19 June 2024. 2. Global Market Insights, www.gminsights.com

Hologic - fFN product development overview and opportunity

Current test: Rapid fFN TLiQ



Next generation test concept (mock-up)

Hologic – the opportunity ahead

- **Verification and validation**
- **Clinical study**
- **Manufacturing**
- **Second test development and IP**

Services Division Updates

Burnet Diagnostics Initiative

- Extension of existing agreement win in August 2024.
- Includes development, regulatory and manufacturing services over a 9 - 12 month period, generating fees between US$0.7 million and US$1.0 million.
- By the end of December 2024, successfully transferred the BDI Alanine Transaminase (ALT) lateral flow test formula into its Carlsbad, California manufacturing site and begun production of ALT test kits for BDI.
- Completed customization activities to its existing camera reader platform and started manufacturing readers for the BDI liver function test.
- BDI's US based clinical trial is expected to start in February 2025 and is likely to be expanded into Australian clinical trials later in 2025.

Priority Catalysts for Growth

"With the successful recent capital raise completed, along with a strong pipeline of projects and partnerships, the Company is well-positioned for continued growth and success."

Doug Ward
MD & Chief Executive Officer
Lumos Diagnostics

Monetize the Lumos-owned, cleared point-of-care test products: FebriDx and ViraDx, through sales, licenses and partnerships

Complete a successful CLIA waiver trial for FebriDx in the US, and achieve FDA label extension. Submit FDA pre-submission for paediatric study

Continue to build the foundation for long-term growth through strategic partnerships, and delivering on milestones relating to the Hologic fFN development agreement

Initiate product development on Lumos branded women's health diagnostics tests

LUMOS
DIAGNOSTICS

www.lumosdiagnostics.com